Schedules of Doxorubicin, Cyclophosphamide, Paclitaxel in High-Risk Early-Stage Breast Cancer Compared

Share this content:

the Cancer Therapy Advisor take:

Adjusted weekly dosing for doxorubicin and cyclophosphamide as well as pacilataxel shows similar disease-free survival rates in patients with early-stage breast cancer, according to a recent study published in the Journal of Clinical Oncology.

Comparing continuous with once-every-two-weeks dosing of doxorubicin and cyclophoshamide, as well as once-a-week with six cycles once-every-two-weeks for pacilataxel, researchers found similar disease-free survival rates in any of these regimens in 3,250 patients.

While overall survival was significantly different in each of the four arms, with all treatments that were given once-every-two-weeks being associated with the highest overall survival, this distinction seemed confined only to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2)-negative tumors. The overall survival rate was similar in patients with hormone receptor-positive/HER2-negative or HER2-positive tumors.

Led by George Budd, MD, of the Cleveland Clinic, the study aimed to determine optimal dosage and scheduling of anthracycline and taxane as adjuvant therapy for early-stage breast cancer. They concluded that, upon subset analysis, once-every-two-weeks dosage may be best for patients with hormone receptor-negative/HER2-negative tumors.

Palbociclib Doubles PFS in Women with Advanced Breast Cancer
Adjusted weekly dosing for doxorubicin and cyclophosphamide as well as pacilataxel shows similar disease-free survival rates.
The authors aimed to determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients achieved a similar disease-free survival (DFS) with any of these regimens.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs